Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and expert literature without systematic review or primary clinical data.
PubMed 35124206 · doi:10.1016/j.phrs.2022.106114
What was done
This narrative review summarizes existing literature on the pharmacological and toxicological mechanisms of metformin, specifically focusing on its modulation of mitochondria and inhibition of complex I in the mitochondrial respiratory chain for potential drug repurposing.
What was found
The abstract reports no numerical data or quantitative outcomes. It qualitatively describes that metformin targets mitochondria by inhibiting complex I of the respiratory chain, though the precise molecular targets and comprehensive mechanisms remain incompletely defined.
Why it matters
Clarifying how metformin interacts with mitochondrial pathways provides a biological framework for understanding its pleiotropic actions and evaluating its potential repurposing for non-diabetic human diseases.
Limits
The abstract provides no primary data, quantitative effect estimates, sample size, or systematic search criteria. It relies on narrative synthesis of mechanistic and preclinical findings, leaving exact molecular mechanisms unresolved.
Cited by
- supports Metformin inhibits mitochondrial complex I, which interferes with mitochondrial function.